PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New insights about brain receptor may pave way for next-gen mental health drugs

Study sheds light on elusive 5-HT1A serotonin receptor, a target of antidepressants and psychedelics

2025-08-01
(Press-News.org) New York, NY [August 1, 2025]— In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights into how a critical brain receptor works at the molecular level and why that matters for mental health treatments.

The study, published in the August 1 online issue of Science Advances, focuses on the 5-HT1A serotonin receptor, a major player in regulating mood and a common target of both traditional antidepressants and newer therapies such as psychedelics. Despite its clinical importance, this receptor has remained poorly understood, with many of its molecular and pharmacological properties largely understudied—until now.

“This receptor is like a control panel that helps manage how brain cells respond to serotonin, a key chemical involved in mood, emotion, and cognition,” says senior author Daniel Wacker, PhD, Assistant Professor of Pharmacological Sciences, and Neuroscience, at the Icahn School of Medicine at Mount Sinai. “Our findings shed light on how that control panel operates—what switches it flips, how it fine-tunes signals, and where its limits lie. This deeper understanding could help us design better therapies for mental health conditions like depression, anxiety, and schizophrenia.”

Using innovative lab techniques, the research team discovered that the 5-HT1A receptor is inherently wired to favor certain cellular signaling pathways over others—regardless of the drug used to target it. However, drugs can still influence the strength with which those pathways are activated. For example, the antipsychotic asenapine (brand name Saphris) was found to selectively engage a specific signaling route due to its relatively weak activity at the receptor.

To explore these mechanisms in greater detail, the researchers combined experiments in lab-grown cells with high-resolution cryo-electron microscopy—a cutting-edge imaging technology that reveals molecular structures at near-atomic resolution. Their work focused on how various drugs activate the 5-HT1A receptor and how the receptor interacts with internal signaling proteins known as G proteins.

Different signaling pathways controlled by the 5-HT1A receptor are linked to different aspects of mood, perception, and even pain. As scientists better understand which pathways are activated, and how, they can more precisely design drugs that treat specific symptoms or conditions without unwanted side effects.

“Our work provides a molecular map of how different drugs ‘push buttons’ on this receptor—activating or silencing specific pathways that influence brain function,” says study first author Audrey L. Warren, PhD, a former student in Dr. Wacker’s lab who is now a postdoctoral researcher at Columbia University. “By understanding exactly how these drugs interact with the receptor, we can start to predict which approaches might lead to more effective or targeted treatments and which ones are unlikely to work. It’s a step toward designing next-generation therapies with greater precision and fewer side effects.”

In a particularly surprising finding, the researchers discovered that a phospholipid—a type of fat molecule found in cell membranes—plays a major role in steering the receptor’s activity, almost like a hidden co-pilot. This is the first time such a role has been observed among the more than 700 known receptors of this type in the human body.

While current antidepressants often take weeks to work, scientists hope this new understanding of 5-HT1A signaling could help explain those delays and lead to faster-acting alternatives.

“This receptor may help explain why standard antidepressants take long to work,” says Dr. Wacker. “By understanding how it functions at a molecular level, we have a clearer path to designing faster, more effective treatments, not just for depression, but also for conditions like psychosis and chronic pain. It’s a key piece of the puzzle.”

Next, the research team plans to dig deeper into the role of the phospholipid "co-factor" and to test how their lab-based findings hold up in more complex experiments. They're also working on turning these discoveries into real-world compounds that could become future psychiatric medications, building on their earlier success with drug candidates derived from psychedelics.

The paper is titled “Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A.”

The study’s authors, as listed in the journal, are Audrey L. Warren, Gregory Zilberg, Anwar Abbassi, Alejandro Abraham, Shifan Yang, and Daniel Wacker.

This work was supported by NIH grant GM133504. Further support came from NIH T32 Training Grant GM062754 and DA053558 and NIH F31 fellowship MH132317.

-####-

About the Icahn School of Medicine at Mount Sinai 

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.  

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows. 

Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges.  More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai

 

 

 

 

 

 

 

 

END



ELSE PRESS RELEASES FROM THIS DATE:

Melanoma ‘sat-nav’ discovery could help curb metastasis

2025-08-01
Researchers have discovered a protein which is critical for steering melanoma cancer cells as they spread throughout the body. The malignant cells become dependent on this protein to migrate, pointing to new strategies for impeding metastasis.  The protein eIF2A is generally thought to spring into action when a cell is under stress, helping ribosomes launch protein synthesis. But according to a study published today in the journal Science Advances, eIF2A has a completely different role in melanoma, helping cancerous cells control movement.  “Malignant cells that metastasize ...

When immune commanders misfire: new insights into rheumatoid arthritis inflammation

2025-08-01
Researchers at Kyoto University have discovered that an immune molecule found only in primates, called IGFL2, plays a key role in regulating inflammation in rheumatoid arthritis (RA). IGFL2 is produced by a subset of immune cells in the joints of patients with RA and acts like fuel on a fire: it activates more immune cells, further amplifying inflammation and worsening joint damage. They also found that IGFL2 levels were much higher in the blood of patients with RA, especially in those with more severe symptoms. These findings support IGFL2’s potential as a diagnostic marker, a tool for monitoring disease progression, ...

SFU researchers develop a new tool that brings blender-like lighting control to any photograph

2025-08-01
Lighting plays a crucial role when it comes to visual storytelling. Whether it’s film or photography, creators spend countless hours, and often significant budgets, crafting the perfect illumination for their shot. But once a photograph or video is captured, the illumination is essentially fixed. Adjusting it afterward, a task called “relighting,” typically demands time-consuming manual work by skilled artists.  While some generative AI tools attempt to tackle this task, they rely on large-scale neural networks and billions of training images to guess how light might interact with a scene. But the process is often ...

Pups in tow, Yellowstone-area wolves trek long distances to stay near prey

2025-08-01
Berkeley — Gray wolf pups are born nearly helpless: blind, deaf and lacking the acute sense of smell of their elders. They usually remain in the safe confines of their den until they are at least three weeks old. That is why UC Berkeley biologists were surprised to observe gray wolves near Yellowstone National Park traveling 20 kilometers or more over rugged, mountainous terrain, with very young pups in tow.  “The first time I saw a camera trap photo of a wolf carrying its pup, I just cracked up because the pup is being carried by its butt,” said Avery Shawler, first author of a new study presenting the findings, which appeared ...

AI breakthrough unlocks 'new' materials to replace lithium-ion batteries

2025-08-01
Researchers from New Jersey Institute of Technology (NJIT) have used artificial intelligence to tackle a critical problem facing the future of energy storage: finding affordable, sustainable alternatives to lithium-ion batteries. In research published in Cell Reports Physical Science, the NJIT team led by Professor Dibakar Datta successfully applied generative AI techniques to rapidly discover new porous materials capable of revolutionizing multivalent-ion batteries. These batteries, using abundant elements like magnesium, calcium, aluminum and zinc, offer a promising, cost-effective alternative to lithium-ion batteries, ...

Making molecules make sense: A regional explanation method reveals structure–property relationships

2025-08-01
In cheminformatics, where machine learning is transforming our understanding of how molecular properties are predicted and explained, a critical challenge has long remained: making these powerful but often "black box" models easier to interpret. Recently, researchers at the Australian National University developed a breakthrough solution: a "regional explanation" method that helps reveal how molecular structures drive their properties. This research was published June 3 in Intelligent ...

Partisan hostility, not just policy, drives U.S. protests

2025-08-01
Partisan animosity is a powerful driver of protest participation -- sometimes nearly matching or even exceeding concern about the actual issues, according to a new study published in the journal Social Forces. The research, conducted by political scientist Seth Warner at the University of Connecticut, analyzed three nationally representative surveys fielded between 2014 and 2022. Each focused on a different protest movement: Black Lives Matter, the climate movement, and the Tea Party. Warner matched survey questions to these movements’ core grievances ...

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 1, 2025

2025-08-01
Reston, VA (August 1, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. Summaries of the newly published research articles are provided below. New Imaging Tool Targets Hidden Liver Tumors Liver cancer is hard to monitor after treatment, ...

Young human blood serum factors show potential to rejuvenate skin through bone marrow

2025-08-01
“[…] we were able to reproduce systemic rejuvenating effects of circulating blood factors on the human skin, which have been so far only demonstrated in rodent heterochronic parabiosis studies.” BUFFALO, NY — August 1, 2025 — A new research paper featured on the cover of Volume 17, Issue 7 of Aging (Aging-US) was published on July 25, 2025, titled “Systemic factors in young human serum influence in vitro responses of human skin and bone marrow-derived blood cells in a microphysiological co-culture system.” The study, led by first author Johanna Ritter and corresponding ...

Large language models reshape the future of task planning

2025-08-01
A comprehensive survey published May 23 in Intelligent Computing, a Science Partner Journal maps out the role of large language models in task planning, underscoring the growing influence of artificial intelligence in complex decision-making tasks. Traditionally reliant on expert systems and manual configuration, task planning is essential for organizing action sequences to achieve defined goals, and is now being redefined by the advanced reasoning capabilities of large language models. The survey offers a comprehensive synthesis of how these models are reshaping ...

LAST 30 PRESS RELEASES:

Study unexpectedly finds living in rural, rather than urban environments in first five years of life could be a risk factor for developing type 1 diabetes

Editorial urges deeper focus on heart-lung interactions in pulmonary vascular disease

Five University of Tennessee faculty receive Fulbright Awards

5 advances to protect water sources, availability

OU Scholar awarded Fulbright for Soviet cinema research

Brain might become target of new type 1 diabetes treatments

‘Shore Wars:’ New research aims to resolve coastal conflict between oysters and mangroves, aiding restoration efforts

Why do symptoms linger in some people after an infection? A conversation on post-acute infection syndromes

Study reveals hidden drivers of asthma flare-ups in children

Physicists decode mysterious membrane behavior

New insights about brain receptor may pave way for next-gen mental health drugs

Melanoma ‘sat-nav’ discovery could help curb metastasis

When immune commanders misfire: new insights into rheumatoid arthritis inflammation

SFU researchers develop a new tool that brings blender-like lighting control to any photograph

Pups in tow, Yellowstone-area wolves trek long distances to stay near prey

AI breakthrough unlocks 'new' materials to replace lithium-ion batteries

Making molecules make sense: A regional explanation method reveals structure–property relationships

Partisan hostility, not just policy, drives U.S. protests

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 1, 2025

Young human blood serum factors show potential to rejuvenate skin through bone marrow

Large language models reshape the future of task planning

Narrower coverage of MS drugs tied to higher relapse risk

Researchers harness AI-powered protein design to enhance T-cell based immunotherapies

Smartphone engagement during school hours among US youths

Online reviews of health care facilities

MS may begin far earlier than previously thought

New AI tool learns to read medical images with far less data

Announcing XPRIZE Healthspan as Tier 5 Sponsor of ARDD 2025

Announcing Immortal Dragons as Tier 4 Sponsor of ARDD 2025

Reporting guideline for chatbot health advice studies

[Press-News.org] New insights about brain receptor may pave way for next-gen mental health drugs
Study sheds light on elusive 5-HT1A serotonin receptor, a target of antidepressants and psychedelics